Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 4,372

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Multiple sclerosis

Compston, Alastair, Coles, Alasdair·2008·The Lancet
DOI 10.1016/s0140-6736(08)61620-7
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(08)61620-7

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 156

  1. McDonald, 2001, Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Ann Neurol, 50, 121, 10.1002/ana.1032 · DOI · Paper page
  2. Polman, 2005, Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”, Ann Neurol, 58, 840, 10.1002/ana.20703 · DOI · Paper page
  3. Confavreux, 2006, Age at disability milestones in multiple sclerosis, Brain, 129, 595, 10.1093/brain/awh714 · DOI · Paper page
  4. Renoux, 2007, Natural history of multiple sclerosis with childhood onset, N Engl J Med, 356, 2603, 10.1056/NEJMoa067597 · DOI · Paper page
  5. Bronnum-Hansen, 2004, Trends in survival and cause of death in Danish patients with multiple sclerosis, Brain, 127, 844, 10.1093/brain/awh104 · DOI · Paper page
  6. Minden, 1990, Affective disorders in multiple sclerosis. Review and recommendations for clinical research, Arch Neurol, 47, 98, 10.1001/archneur.1990.00530010124031 · DOI · Paper page
  7. Vukusic, 2004, Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse, Brain, 127, 1353, 10.1093/brain/awh152 · DOI · Paper page
  8. Buljevac, 2002, Prospective study on the relationship between infections and multiple sclerosis exacerbations, Brain, 125, 952, 10.1093/brain/awf098 · DOI · Paper page
  9. Andersen, 1993, Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study, J Neurol, 240, 417, 10.1007/BF00867354 · DOI · Paper page
  10. Correale, 2007, Association between parasite infection and immune responses in multiple sclerosis, Ann Neurol, 61, 97, 10.1002/ana.21067 · DOI · Paper page
  11. Confavreux, 2001, Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group, N Engl J Med, 344, 319, 10.1056/NEJM200102013440501 · DOI · Paper page
  12. Kurtzke, 1975, A reassessment of the distribution of multiple sclerosis. Part one, Acta Neurol Scand, 51, 110, 10.1111/j.1600-0404.1975.tb01364.x · DOI
  13. Orton, 2006, Sex ratio of multiple sclerosis in Canada: a longitudinal study, Lancet Neurol, 5, 932, 10.1016/S1474-4422(06)70581-6 · DOI · Paper page
  14. Dean, 1971, On the risk of multiple sclerosis according to age at immigration to South Africa, Br Med J, 3, 725, 10.1136/bmj.3.5777.725 · DOI · Paper page
  15. Alter, 1962, Multiple sclerosis in Israel. Prevalence among immigrants and native inhabitants, Arch Neurol, 7, 253, 10.1001/archneur.1962.04210040005001 · DOI
  16. Detels, 1977, Evidence for lower susceptibility to multiple sclerosis in Japanese-Americans, Am J Epidemiol, 105, 303, 10.1093/oxfordjournals.aje.a112387 · DOI
  17. Elian, 1990, Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa and the West Indies, J Neurol Neurosurg Psychiatry, 53, 906, 10.1136/jnnp.53.10.906 · DOI
  18. Hammond, 2000, The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia, Brain, 123, 968, 10.1093/brain/123.5.968 · DOI
  19. Martyn, 1993, Symptomatic Epstein-Barr virus infection and multiple sclerosis, J Neurol Neurosurg Psychiatry, 56, 167, 10.1136/jnnp.56.2.167 · DOI
  20. Levin, 2003, Multiple sclerosis and Epstein-Barr virus, JAMA, 289, 1533, 10.1001/jama.289.12.1533 · DOI
  21. Lang, 2002, A functional and structural basis for TCR cross-reactivity in multiple sclerosis, Nat Immunol, 3, 940, 10.1038/ni835 · DOI · Paper page
  22. Magliozzi, 2007, Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain, J Exp Med, 204, 2899, 10.1084/jem.20071030 · DOI · Paper page
  23. Mikaeloff, 2007, Parental smoking at home and the risk of childhood-onset multiple sclerosis in children, Brain, 130, 2589, 10.1093/brain/awm198 · DOI
  24. Hernan, 2005, Cigarette smoking and the progression of multiple sclerosis, Brain, 128, 1461, 10.1093/brain/awh471 · DOI · Paper page
  25. Marrie, 2004, Environmental risk factors in multiple sclerosis aetiology, Lancet Neurol, 3, 709, 10.1016/S1474-4422(04)00933-0 · DOI · Paper page
  26. Robertson, 1996, Clinical concordance in sibling pairs with multiple sclerosis, Neurology, 47, 347, 10.1212/WNL.47.2.347 · DOI
  27. Carton, 1997, Risks of multiple sclerosis in relatives of patients in Flanders, Belgium, J Neurol Neurosurg Psychiatry, 62, 329, 10.1136/jnnp.62.4.329 · DOI
  28. Robertson, 1996, Age-adjusted recurrence risks for relatives of patients with multiple sclerosis, Brain, 119, 449, 10.1093/brain/119.2.449 · DOI · Paper page
  29. Sadovnick, 1988, The familial nature of multiple sclerosis: age-corrected empiric recurrence risks for children and siblings of patients, Neurology, 38, 990, 10.1212/WNL.38.6.990 · doi:10.1212/wnl.38.6.990
  30. Willer, 2003, Twin concordance and sibling recurrence rates in multiple sclerosis, Proc Natl Acad Sci USA, 100, 12877, 10.1073/pnas.1932604100 · DOI · Paper page
  31. Mumford, 1994, The British Isles survey of multiple sclerosis in twins, Neurology, 44, 11, 10.1212/WNL.44.1.11 · DOI · Paper page
  32. 1992, Multiple sclerosis in 54 twinships: concordance rate is independent of zygosity. French Research Group on Multiple Sclerosis, Ann Neurol, 32, 724, 10.1002/ana.410320604 · DOI
  33. Ristori, 2006, Multiple sclerosis in twins from continental Italy and Sardinia: a nationwide study, Ann Neurol, 59, 27, 10.1002/ana.20683 · doi:10.1002/ana.20683
  34. Ebers, 1995, A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group, Nature, 377, 150, 10.1038/377150a0 · DOI · Paper page
  35. Dyment, 2006, Multiple sclerosis in stepsiblings: recurrence risk and ascertainment, J Neurol Neurosurg Psychiatry, 77, 258, 10.1136/jnnp.2005.063008 · DOI
  36. Robertson, 1997, Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis, Lancet, 349, 1587, 10.1016/S0140-6736(96)07317-5 · DOI
  37. Ebers, 2000, Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Canadian Collaborative Study Group, Ann Neurol, 48, 927, 10.1002/1531-8249(200012)48:6<927::AID-ANA14>3.0.CO;2-F · doi:10.1002/1531-8249(200012)48:6<927::aid-ana14>3.0.co;2-f
  38. Broadley, 2000, Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey, Brain, 123, 1102, 10.1093/brain/123.6.1102 · DOI
  39. Ramagopalan, 2007, Autoimmune disease in families with multiple sclerosis: a population-based study, Lancet Neurol, 6, 604, 10.1016/S1474-4422(07)70132-1 · DOI · Paper page
  40. Compston, 1976, B-lymphocyte alloantigens associated with multiple sclerosis, Lancet, 308, 1261, 10.1016/S0140-6736(76)92027-4 · DOI
  41. Terasaki, 1976, Multiple sclerosis and high incidence of a B lymphocyte antigen, Science, 193, 1245, 10.1126/science.1085490 · DOI
  42. Olerup, 1991, HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation, Tissue Antigens, 38, 1, 10.1111/j.1399-0039.1991.tb02029.x · DOI · Paper page
  43. Marrosu, 1992, HLA-DQB1 genotype in Sardinian multiple sclerosis: evidence for a key role of DQB1 *0201 and *0302 alleles, Neurology, 42, 883, 10.1212/WNL.42.4.883 · DOI
  44. Sawcer, 1996, A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22, Nat Genet, 13, 464, 10.1038/ng0896-464 · DOI · Paper page
  45. 2006, Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans, J Neuroimmunol, 179, 108, 10.1016/j.jneuroim.2006.06.003 · DOI
  46. Tienari, 1998, Golli-MBP gene in multiple sclerosis susceptibility, J Neuroimmunol, 81, 158, 10.1016/S0165-5728(97)00171-9 · DOI
  47. Reich, 2005, A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility, Nat Genet, 37, 1113, 10.1038/ng1646 · DOI · Paper page
  48. Yeo, 2007, A second major histocompatibility complex susceptibility locus for multiple sclerosis, Ann Neurol, 61, 228, 10.1002/ana.21063 · DOI
  49. Dean, 2008, HLA-DRB1 and multiple sclerosis in Malta, Neurology, 70, 101, 10.1212/01.wnl.0000284598.98525.d7 · DOI
  50. Ramagopalan, 2007, The inheritance of resistance alleles in multiple sclerosis, PLoS Genet, 3, 1607, 10.1371/journal.pgen.0030150 · DOI
  51. Gregory, 2007, Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis, Nat Genet, 39, 1083, 10.1038/ng2103 · DOI · Paper page
  52. 2008, Refining genetic associations in multiple sclerosis, Lancet Neurol, 7, 567, 10.1016/S1474-4422(08)70122-4 · DOI
  53. Dawson, 1916, The histology of disseminated sclerosis, Trans R Soc Edinb, 50, 517, 10.1017/S0080456800027174 · DOI · Paper page
  54. Coman, 2006, Nodal, paranodal and juxtaparanodal axonal proteins during demyelination and remyelination in multiple sclerosis, Brain, 129, 3186, 10.1093/brain/awl144 · DOI · Paper page
  55. Raff, 1983, A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium, Nature, 303, 390, 10.1038/303390a0 · DOI · Paper page
  56. Viglietta, 2004, Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis, J Exp Med, 199, 971, 10.1084/jem.20031579 · DOI · Paper page
  57. Shi, 2007, Critical regulation of CD4+ T cell survival and autoimmunity by beta-arrestin 1, Nat Immunol, 8, 817, 10.1038/ni1489 · DOI
  58. Tzartos, 2008, Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis, Am J Pathol, 172, 146, 10.2353/ajpath.2008.070690 · DOI · Paper page
  59. Ousman, 2007, Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination, Nature, 448, 474, 10.1038/nature05935 · DOI · Paper page
  60. Mathey, 2007, Neurofascin as a novel target for autoantibody-mediated axonal injury, J Exp Med, 204, 2363, 10.1084/jem.20071053 · DOI · Paper page
  61. Zajicek, 1992, Interactions between oligodendrocytes and microglia. A major role for complement and tumour necrosis factor in oligodendrocyte adherence and killing, Brain, 115, 1611, 10.1093/brain/115.6.1611-a · DOI
  62. Ferguson, 1997, Axonal damage in acute multiple sclerosis lesions, Brain, 120, 393, 10.1093/brain/120.3.393 · DOI · Paper page
  63. Kuhlmann, 2002, Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time, Brain, 125, 2202, 10.1093/brain/awf235 · DOI · Paper page
  64. Anderson, 2008, Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis, Brain, 131, 1736, 10.1093/brain/awn119 · DOI · Paper page
  65. Kutzelnigg, 2005, Cortical demyelination and diffuse white matter injury in multiple sclerosis, Brain, 128, 2705, 10.1093/brain/awh641 · DOI · Paper page
  66. Zeis, 2008, Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection, Brain, 131, 288, 10.1093/brain/awm291 · DOI · Paper page
  67. Magliozzi, 2007, Meningeal B-cell follicles in secondary progressive multiple sclerosis associated with early onset of disease and severe cortical pathology, Brain, 130, 1089, 10.1093/brain/awm038 · DOI · Paper page
  68. Williams, 2007, Semaphorin 3A and 3F: key players in myelin repair in multiple sclerosis?, Brain, 130, 2554, 10.1093/brain/awm202 · DOI
  69. Scolding, 1998, Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis, Brain, 121, 2221, 10.1093/brain/121.12.2221 · DOI · Paper page
  70. Wolswijk, 1998, Oligodendrocyte regeneration in the adult rodent CNS and the failure of this process in multiple sclerosis, Prog Brain Res, 117, 233, 10.1016/S0079-6123(08)64019-4 · DOI
  71. Chandran, 2008, Myelin repair: the role of stem and precursor cells in multiple sclerosis, Philos Trans R Soc Lond B Biol Sci, 363, 171, 10.1098/rstb.2006.2019 · DOI
  72. Patrikios, 2006, Remyelination is extensive in a subset of multiple sclerosis patients, Brain, 129, 3165, 10.1093/brain/awl217 · DOI · Paper page
  73. Davie, 1995, Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss, Brain, 118, 1583, 10.1093/brain/118.6.1583 · DOI · Paper page
  74. Filippi, 2003, Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis, Brain, 126, 433, 10.1093/brain/awg038 · DOI · Paper page
  75. Kuhle, 2007, Lack of association between antimyelin antibodies and progression to multiple sclerosis, N Engl J Med, 356, 371, 10.1056/NEJMoa063602 · DOI · Paper page
  76. Belogurov, 2008, Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis, J Immunol, 180, 1258, 10.4049/jimmunol.180.2.1258 · doi:10.4049/jimmunol.180.2.1258
  77. Eikelenboom, 2003, Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy, Neurology, 60, 219, 10.1212/01.WNL.0000041496.58127.E3 · DOI
  78. Youl, 1991, The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits, Brain, 114, 2437, 10.1093/brain/114.6.2437 · DOI · Paper page
  79. Black, 2006, Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE, Brain, 129, 3196, 10.1093/brain/awl216 · DOI
  80. Smith, 2006, Axonal protection in multiple sclerosis—a particular need during remyelination?, Brain, 129, 3147, 10.1093/brain/awl323 · DOI
  81. Smith, 1981, The restoration of conduction by central demyelination, Brain, 104, 383, 10.1093/brain/104.2.383 · DOI · Paper page
  82. Hensiek, 2007, Familial effects on the clinical course of multiple sclerosis, Neurology, 68, 376, 10.1212/01.wnl.0000252822.53506.46 · DOI
  83. Kremenchutzky, 2006, The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease, Brain, 129, 584, 10.1093/brain/awh721 · DOI · Paper page
  84. Redford, 1997, Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible, Brain, 120, 2149, 10.1093/brain/120.12.2149 · DOI · Paper page
  85. Smith, 2001, Electrically active axons degenerate when exposed to nitric oxide, Ann Neurol, 49, 470, 10.1002/ana.96 · DOI · Paper page
  86. Golde, 2002, Different pathways for iNOS-mediated toxicity in vitro dependent on neuronal maturation and NMDA receptor expression, J Neurochem, 82, 269, 10.1046/j.1471-4159.2002.00973.x · DOI
  87. Dutta, 2006, Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients, Ann Neurol, 59, 478, 10.1002/ana.20736 · DOI · Paper page
  88. Howell, 2006, Disruption of neurofascin localization reveals early changes preceding demyelination and remyelination in multiple sclerosis, Brain, 129, 3173, 10.1093/brain/awl290 · DOI · Paper page
  89. Wilkins, 2001, A role for oligodendrocyte-derived IGF-1 in trophic support of cortical neurons, Glia, 36, 48, 10.1002/glia.1094 · DOI
  90. Wilkins, 2005, Trophic factors attenuate nitric oxide mediated neuronal and axonal injury in vitro: roles and interactions of mitogen-activated protein kinase signalling pathways, J Neurochem, 92, 1487, 10.1111/j.1471-4159.2004.02981.x · DOI
  91. Kellar-Wood, 1994, Leber's hereditary optic neuropathy mitochondrial DNA mutations in multiple sclerosis, Ann Neurol, 36, 109, 10.1002/ana.410360121 · DOI · Paper page
  92. Harding, 1992, Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation, Brain, 115, 979, 10.1093/brain/115.4.979 · DOI · Paper page
  93. Riordan-Eva, 1995, The clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation, Brain, 118, 319, 10.1093/brain/118.2.319 · DOI · Paper page
  94. Lucchinetti, 2000, Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination, Ann Neurol, 47, 707, 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q · doi:10.1002/1531-8249(200006)47:6<707::aid-ana3>3.0.co;2-q
  95. Lucchinetti, 1996, Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis, Brain Pathol, 6, 259, 10.1111/j.1750-3639.1996.tb00854.x · DOI · Paper page
  96. Mahad, 2008, Mitochondrial defects in acute multiple sclerosis lesions, Brain, 131, 1722, 10.1093/brain/awn105 · DOI · Paper page
  97. Breij, 2008, Homogeneity of active demyelinating lesions in established multiple sclerosis, Ann Neurol, 63, 16, 10.1002/ana.21311 · DOI · Paper page
  98. Lucchinetti, 2002, A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica, Brain, 125, 1450, 10.1093/brain/awf151 · DOI · Paper page
  99. Stadelmann, 2005, Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis, Brain, 128, 979, 10.1093/brain/awh457 · DOI · Paper page
  100. Lennon, 2004, A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis, Lancet, 364, 2106, 10.1016/S0140-6736(04)17551-X · DOI · Paper page
  101. Lennon, 2005, IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel, J Exp Med, 202, 473, 10.1084/jem.20050304 · DOI · Paper page
  102. Wingerchuk, 1999, The clinical course of neuromyelitis optica (Devic's syndrome), Neurology, 53, 1107, 10.1212/WNL.53.5.1107 · DOI · Paper page
  103. Wingerchuk, 2006, Revised diagnostic criteria for neuromyelitis optica, Neurology, 66, 1485, 10.1212/01.wnl.0000216139.44259.74 · DOI · Paper page
  104. Roemer, 2007, Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis, Brain, 130, 1194, 10.1093/brain/awl371 · DOI · Paper page
  105. Misu, 2007, Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis, Brain, 130, 1224, 10.1093/brain/awm047 · DOI · Paper page
  106. Keegan, 2005, Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange, Lancet, 366, 579, 10.1016/S0140-6736(05)67102-4 · DOI · Paper page
  107. Matsuoka, 2007, Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese, Brain, 130, 1206, 10.1093/brain/awm027 · DOI · Paper page
  108. Kira, 1999, Changes in the clinical phenotypes of multiple sclerosis during the past 50 years in Japan, J Neurol Sci, 166, 53, 10.1016/S0022-510X(99)00115-X · DOI
  109. Cabre, 2005, Role of return migration in the emergence of multiple sclerosis in the French West Indies, Brain, 128, 2899, 10.1093/brain/awh624 · DOI
  110. Compston, 2004, The marvellous harmony of the nervous parts: the origins of multiple sclerosis, Clin Med, 4, 346, 10.7861/clinmedicine.4-4-346 · DOI
  111. Miller, 2000, A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations, Mult Scler, 6, 267, 10.1177/135245850000600408 · DOI
  112. Weinshenker, 1999, A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease, Ann Neurol, 46, 878, 10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q · DOI · Paper page
  113. Keegan, 2002, Plasma exchange for severe attacks of CNS demyelination: predictors of response, Neurology, 58, 143, 10.1212/WNL.58.1.143 · DOI · Paper page
  114. Ebers, 1998, Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis, Lancet, 352, 1498, 10.1016/S0140-6736(98)03334-0 · DOI · Paper page
  115. Jacobs, 1996, Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis, Ann Neurol, 39, 285, 10.1002/ana.410390304 · DOI · Paper page
  116. Duquette, 1995, Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial, Neurology, 45, 1277, 10.1212/WNL.45.7.1277 · DOI · Paper page
  117. Johnson, 1995, Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group, Neurology, 45, 1268, 10.1212/WNL.45.7.1268 · DOI · Paper page
  118. Paty, 1993, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology, 43, 662, 10.1212/WNL.43.4.662 · DOI · Paper page
  119. Panitch, 1987, Exacerbations of multiple sclerosis in patients treated with gamma interferon, Lancet, 1, 893, 10.1016/S0140-6736(87)92863-7 · DOI · Paper page
  120. Yudkin, 1991, Overview of azathioprine treatment in multiple sclerosis, Lancet, 338, 1051, 10.1016/0140-6736(91)91909-E · DOI
  121. Schmied, 2003, In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis, Clin Immunol, 106, 163, 10.1016/S1521-6616(03)00020-2 · DOI
  122. 2001, PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS, Neurology, 56, 1628, 10.1212/WNL.56.12.1628 · DOI · Paper page
  123. 2000, Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis, N Engl J Med, 343, 898, 10.1056/NEJM200009283431301 · DOI · Paper page
  124. Comi, 2001, Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study, Lancet, 357, 1576, 10.1016/S0140-6736(00)04725-5 · DOI · Paper page
  125. Kappos, 2007, Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study, Lancet, 370, 389, 10.1016/S0140-6736(07)61194-5 · DOI · Paper page
  126. Comi, 2008, Treatment with glatiramer acetate delays conversion to clinically definite multiple sclerosis in patients with clinically isao.lated syndromes suggestive of multiple sclerosis, J Neurology, 255, 10
  127. Kinkel, 2006, IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event, Neurology, 66, 678, 10.1212/01.wnl.0000200778.65597.ae · DOI · Paper page
  128. 2001, Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results, Neurology, 56, 1496, 10.1212/WNL.56.11.1496 · DOI · Paper page
  129. Panitch, 2004, Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study, Neurology, 63, 1788, 10.1212/01.WNL.0000146958.77317.3E · DOI · Paper page
  130. Cohen, 2002, Benefit of interferon beta-1a on MSFC progression in secondary progressive MS, Neurology, 59, 679, 10.1212/WNL.59.5.679 · DOI · Paper page
  131. Kappos, 1998, Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis, Lancet, 352, 1491, 10.1016/S0140-6736(98)10039-9 · DOI · Paper page
  132. Miller, 1999, Ann Neurol, 46, 850, 10.1002/1531-8249(199912)46:6<850::AID-ANA7>3.0.CO;2-Q · DOI
  133. Wolinsky, 2007, Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial, Ann Neurol, 61, 14, 10.1002/ana.21079 · DOI · Paper page
  134. Sorensen, 2003, Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis, Lancet, 362, 1184, 10.1016/S0140-6736(03)14541-2 · DOI · Paper page
  135. Panitch, 2002, Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial, Neurology, 59, 1496, 10.1212/01.WNL.0000034080.43681.DA · DOI · Paper page
  136. Durelli, 2002, Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN), Lancet, 359, 1453, 10.1016/S0140-6736(02)08430-1 · DOI · Paper page
  137. Filippi, 2008, Magentic resonance imaging findings of a phase III trial comparing Betaferon with Copaxone treatments in relapsing-remitting multiple sclerosis, J Neurology, 255, 9
  138. Filippini, 2003, Interferons in relapsing remitting multiple sclerosis: a systematic review, Lancet, 361, 545, 10.1016/S0140-6736(03)12512-3 · DOI · Paper page
  139. Munari, 2004, Lack of evidence for use of glatiramer acetate in multiple sclerosis, Lancet Neurol, 3, 641, 10.1016/S1474-4422(04)00899-3 · doi:10.1016/s1474-4422(04)00899-3
  140. Cohen, 2007, Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS, Neurology, 68, 939, 10.1212/01.wnl.0000257109.61671.06 · doi:10.1212/01.wnl.0000257109.61671.06
  141. Le Page, 2008, Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients, J Neurol Neurosurg Psychiatry, 79, 52, 10.1136/jnnp.2007.124958 · doi:10.1136/jnnp.2007.124958
  142. Edan, 1997, Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria, J Neurol Neurosurg Psychiatry, 62, 112, 10.1136/jnnp.62.2.112 · DOI · Paper page
  143. Hartung, 2002, Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial, Lancet, 360, 2018, 10.1016/S0140-6736(02)12023-X · DOI · Paper page
  144. Yednock, 1992, Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin, Nature, 356, 63, 10.1038/356063a0 · DOI · Paper page
  145. Polman, 2006, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, 354, 899, 10.1056/NEJMoa044397 · DOI · Paper page
  146. Rudick, 2006, Natalizumab plus interferon beta-1a for relapsing multiple sclerosis, N Engl J Med, 354, 911, 10.1056/NEJMoa044396 · DOI · Paper page
  147. Kappos, 2006, Oral fingolimod (FTY720) for relapsing multiple sclerosis, N Engl J Med, 355, 1124, 10.1056/NEJMoa052643 · DOI · Paper page
  148. Comi, 2008, Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study, Lancet, 371, 2085, 10.1016/S0140-6736(08)60918-6 · DOI · Paper page
  149. Kappos, 2008, Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study, Lancet, 372, 1463, 10.1016/S0140-6736(08)61619-0 · DOI · Paper page
  150. Achiron, 2004, T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients, Clin Immunol, 113, 155, 10.1016/j.clim.2004.06.004 · doi:10.1016/j.clim.2004.06.004
  151. Bielekova, 2004, Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta, Proc Natl Acad Sci USA, 101, 8705, 10.1073/pnas.0402653101 · DOI · Paper page
  152. Coles, 1999, Pulsed monoclonal antibody treatment and thyroid autoimmunity in multiple sclerosis, Lancet, 354, 1691, 10.1016/S0140-6736(99)02429-0 · DOI · Paper page
  153. Coles, 2006, The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy, J Neurol, 253, 98, 10.1007/s00415-005-0934-5 · DOI · Paper page
  154. 2008, Alemtuzumab vs. interferon beta-1a in early multiple sclerosis, N Engl J Med, 359, 30
  155. Saccardi, 2006, Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database, Mult Scler, 12, 814, 10.1177/1352458506071301 · DOI · Paper page
  156. Metz, 2007, Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis, Brain, 130, 1254, 10.1093/brain/awl370 · DOI

Cited by

See all 4,372

Metadata

Authors
Compston, A., & Coles, A.
Venue
The Lancet
Publisher
Elsevier BV
Published
2008-10
Volume
372
Issue
9648
Pages
1502-1517
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(08)61620-7
OpenAlex
W4211254511
Cited by
4,372
References
12
FWCI
71.41
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multiple sclerosis. https://app.cochat.ai/papers/10.1016/s0140-6736(08)61620-7
The paper
Compston, A., & Coles, A. (2008). Multiple sclerosis. The Lancet. https://doi.org/10.1016/s0140-6736(08)61620-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.